论文部分内容阅读
目的本研究旨在明确急性心肌梗死(AMI)患者骨髓单个核细胞(MBMC)移植前后,尾加压素Ⅱ和脑钠肽的变化。方法 23例AMI患者(AMI组)与22例无冠状动脉病变的患者(对照组)做对照,AMI组MBMC移植前,移植后1、7d,对照组入选时放射免疫法测定血浆尾加压素Ⅱ和脑钠肽水平。结果 AMI组尾加压素Ⅱ水平在MBMC移植前[(0.374±0.189)ng/ml]较对照组[(0.046±0.017)ng/ml]显著升高(P<0.01),移植后[(0.223±0.043)ng/ml]较对照组[(0.462±0.115)ng/ml]显著降低(P<0.01),移植1d后显著升高,和移植前相比增加到129%,移植后7d再次降低。AMI组脑钠肽水平,在MBMC移植后1d与移植前相比降低到61%,移植后7d降低更明显。结论 MBMC移植的疗效可能与其对尾加压素Ⅱ和脑钠肽水平的调节有关。
Objectives This study was designed to determine the changes of urotensin Ⅱ and brain natriuretic peptide before and after transplantation of bone marrow mononuclear cells (MBMC) in patients with acute myocardial infarction (AMI). Methods 23 AMI patients (AMI group) were compared with 22 patients without coronary artery disease (control group). AMI group before MBMC transplantation, 1,7d after transplantation, the control group was selected radioimmunoassay urotensin Ⅱ and brain natriuretic peptide levels. Results The urotensin Ⅱ level in AMI group was significantly higher than that in control group [(0.046 ± 0.017) ng / ml] [(0.374 ± 0.189) ng / ml vs ± 0.043) ng / ml] was significantly lower than that of the control group [(0.462 ± 0.115) ng / ml] (P <0.01), significantly increased after 1 day of transplantation, increased to 129% . The level of brain natriuretic peptide in AMI group decreased to 61% 1 d after transplantation compared with that before transplantation, and decreased more obviously 7 days after transplantation. Conclusion The efficacy of MBMC transplantation may be related to the regulation of urotensin Ⅱ and brain natriuretic peptide.